dc.contributor.advisor |
Gash, D |
en |
dc.contributor.advisor |
Winters, B |
en |
dc.contributor.advisor |
Turnbull, A |
en |
dc.contributor.author |
Beasley, Charles |
en |
dc.date.accessioned |
2014-04-13T21:55:27Z |
en |
dc.date.issued |
2013 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/21973 |
en |
dc.description |
Full text is available to authenticated members of The University of Auckland only. |
en |
dc.description.abstract |
In the developed world, the incidence of atopic dermatitis, a highly pruritic skin disease of both adults and children, is on the rise. A number of different therapies are available, the majority of which are focussed on the topical application of a variety of different drugs prepared as creams or ointments. The most potent of these have the potential for significant adverse effects. Lypanosys’ proprietary drug LYP-010 is a novel therapy for atopic dermatitis. Its active ingredients, route of administration and mechanism of action are different to current standards of care. Based on data from use of LYP-010 and its constituents as ingredients in marketed nutritional supplements, the drug is safe. In order to optimise the commercial development of LYP-010, Lypanosys plans to seek a suitable development partner. In order to better communicate the potential cost-effectiveness of LYP-010, a pharmacoeconomic model to support reimbursement applications needs to be constructed. The objective of this thesis is the construction of a novel pharmacoeconomic model that can be used to determine the cost-effectiveness of LYP-010. The focus is not the pharmacoeconomic output of the model, but the construction of the novel model itself. A systematic review was carried out to identify existing models, and to determine their applicability to a model for LYP-010. The main findings of this research indicate that a diverse array of different atopic dermatitis pharmacoeconomic models has been developed. However, given the unique characteristics of LYP-010 and the nature of the clinical efficacy data available, not all of these models were appropriate. It was found that a cost-utility Markov model built on disease or health states was the most suitable for LYP-010. This model can be used to its full potential once more robust LYP-010 clinical efficacy data become available. |
en |
dc.publisher |
ResearchSpace@Auckland |
en |
dc.relation.ispartof |
Masters Thesis - University of Auckland |
en |
dc.relation.isreferencedby |
UoA99264741005202091 |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights |
Restricted Item. Available to authenticated members of The University of Auckland. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.rights.uri |
http://creativecommons.org/licenses/by-nc-sa/3.0/nz/ |
en |
dc.title |
Pharmacoeconomic considerations for a novel atopic dermatitis therapeutic |
en |
dc.type |
Thesis |
en |
thesis.degree.discipline |
Bioscience Enterprise |
en |
thesis.degree.grantor |
The University of Auckland |
en |
thesis.degree.level |
Masters |
en |
dc.rights.holder |
Copyright: The Author |
en |
pubs.elements-id |
434681 |
en |
pubs.record-created-at-source-date |
2014-04-14 |
en |
dc.identifier.wikidata |
Q112899458 |
|